{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:09:06Z","timestamp":1784113746320,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.seizure.2026.05.031","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:40:38Z","timestamp":1780443638000},"page":"193-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Switching from oxcarbazepine to eslicarbazepine in patients with focal epilepsy: A systematic review and single-arm meta-analysis"],"prefix":"10.1016","volume":"140","author":[{"given":"Samuel Oliveira","family":"de Amorim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan Fellipe Cardoso","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus da Silva","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4476-2357","authenticated-orcid":false,"given":"Cid","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Henrique Lima","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0631-2565","authenticated-orcid":false,"given":"Rayan Moura Patrik","family":"Naim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit\u00f3ria Caroline Lopes","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1607-9976","authenticated-orcid":false,"given":"Jos\u00e9 Alexandre","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-7293","authenticated-orcid":false,"given":"Jonata Ribeiro","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Manoel","family":"Honorato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2026.05.031_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.26815\/acn.2025.00850","article-title":"Real-world efficacy and tolerability of switching from oxcarbazepine to eslicarbazepine therapy in children aged 6 years or older with focal epilepsy","volume":"33","author":"Lyu","year":"2025","journal-title":"Ann Child Neurol"},{"key":"10.1016\/j.seizure.2026.05.031_bib0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.seizure.2019.12.022","article-title":"Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice","volume":"75","author":"Rocamora","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2026.05.031_bib0003","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"On behalf of the BIA-2093-301 investigators study group. efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.031_bib0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.05.031_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"on behalf of the BIA-2093-303 investigators study group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2026.05.031_bib0006","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.031_bib0007","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/j.1528-1167.2010.02660.x","article-title":"Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy","volume":"51","author":"Hal\u00e1sz","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.031_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2022.107552","article-title":"Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial","volume":"225","author":"Aboumatar","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.seizure.2026.05.031_bib0009","series-title":"The cochrane collaboration, editor. cochrane database syst. rev.","article-title":"Eslicarbazepine acetate add-on for drug-resistant partial epilepsy","author":"Chang","year":"2011"},{"key":"10.1016\/j.seizure.2026.05.031_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106561","article-title":"Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures","volume":"171","author":"Hixson","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.05.031_bib0011","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/epi.12242","article-title":"Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers","volume":"54","author":"Elger","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.031_bib0012","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-1211(01)00231-5","article-title":"Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(\u2212)-10,11-dihydro-10-hydroxy carbamazepine","volume":"44","author":"Hainzl","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.05.031_bib0013","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide","volume":"89","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.seizure.2026.05.031_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.124","article-title":"Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action","volume":"3","author":"Soares-da-Silva","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.seizure.2026.05.031_bib0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.seizure.2026.05.031_bib0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ane.12803","article-title":"Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy","volume":"137","author":"Lattanzi","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2026.05.031_bib0017","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40120-018-0111-2","article-title":"Dibenzazepine agents in epilepsy: how does eslicarbazepine acetate differ?","volume":"7","author":"Lawthom","year":"2018","journal-title":"Neurol Ther"},{"key":"10.1016\/j.seizure.2026.05.031_bib0018","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","article-title":"Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","volume":"22","author":"Zaccara","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2026.05.031_bib0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/08830738241282903","article-title":"The initial experience of eslicarbazepine in children at three Canadian tertiary pediatric Care centers","volume":"40","author":"Nyakeri","year":"2025","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2026.05.031_bib0020","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/epi.14014","article-title":"Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine","volume":"59","author":"Pazdera","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.031_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-000858","article-title":"Synthesising quantitative evidence in systematic reviews of complex health interventions","volume":"4","author":"Higgins","year":"2019","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.seizure.2026.05.031_bib0022","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2026.05.031_bib0023","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.seizure.2026.05.031_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2026.05.031_bib0025","first-page":"55","article-title":"Robvis: an R package and shiny web app for visualizing risk-of-bias assessments","volume":"11","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.seizure.2026.05.031_bib0026","unstructured":"R Project: What is R? n.d."},{"key":"10.1016\/j.seizure.2026.05.031_bib0027","doi-asserted-by":"crossref","unstructured":"Schwarzer G. Meta: general package for meta-analysis 2006:8.2-1. https:\/\/doi.org\/10.32614\/CRAN.package.meta.","DOI":"10.32614\/CRAN.package.meta"},{"key":"10.1016\/j.seizure.2026.05.031_bib0028","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s00115-010-3177-3","article-title":"Abrupter Austausch von retardiertem Oxcarbazepin gegen eslicarbazepinacetat","volume":"82","author":"Steinhoff","year":"2011","journal-title":"Nervenarzt"},{"key":"10.1016\/j.seizure.2026.05.031_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110568","article-title":"Switching from oxcarbazepine to eslicarbazepine in pediatric patients with focal epilepsy is safe and well-tolerated","volume":"173","author":"Shim","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2026.05.031_bib0030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ane.12645","article-title":"Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study","volume":"135","author":"Schmid","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2026.05.031_bib0031","first-page":"94","article-title":"Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results","volume":"29","author":"Massot","year":"2014","journal-title":"Neurol Engl Ed"},{"key":"10.1016\/j.seizure.2026.05.031_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.634","article-title":"Transition from oxcarbazepine to eslicarbazepine acetate: a single center study","volume":"7","author":"M\u00e4kinen","year":"2017","journal-title":"Brain Behav"},{"key":"10.1016\/j.seizure.2026.05.031_bib0033","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.eplepsyres.2014.04.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study","volume":"108","author":"Villanueva","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.05.031_bib0034","series-title":"Oxcarbazepine. statpearls internet","author":"Preuss","year":"2024"},{"key":"10.1016\/j.seizure.2026.05.031_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107285","article-title":"Efficacy, safety, and tolerability of adjunctive eslicarbazepine acetate in patients with focal to bilateral tonic-clonic seizures","volume":"200","author":"Chung","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.05.031_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.909471","article-title":"Adjunctive treatment with eslicarbazepine acetate for adults and children with focal-onset epilepsy: a meta-analysis","volume":"13","author":"Fei","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2026.05.031_bib0037","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","article-title":"Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","volume":"22","author":"Zaccara","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2026.05.031_bib0038","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/00207454.2021.1925667","article-title":"Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies","volume":"133","author":"Fern\u00e1ndez-Anaya","year":"2023","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.seizure.2026.05.031_bib0039","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40263-018-0504-x","article-title":"Adjunctive eslicarbazepine acetate in pediatric patients with focal epilepsy: a systematic review and meta-analysis","volume":"32","author":"Lattanzi","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2026.05.031_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107458","article-title":"Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures","volume":"112","author":"Sankar","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2026.05.031_bib0041","article-title":"Eslicarbazepine acetate add-on for drug-resistant focal epilepsy","volume":"2018","author":"Chang","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2026.05.031_bib0042","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40120-021-00244-5","article-title":"Healthcare resource utilization among patients with focal seizures treated with eslicarbazepine acetate in the US long-term care setting: a retrospective claims database analysis","volume":"10","author":"Mehta","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.seizure.2026.05.031_bib0043","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40120-020-00211-6","article-title":"Impact of early initiation of eslicarbazepine acetate on economic outcomes among patients with focal seizure: results from retrospective database analyses","volume":"9","author":"Mehta","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.seizure.2026.05.031_bib0044","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ane.12574","article-title":"Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy","volume":"134","author":"Holtkamp","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2026.05.031_bib0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.seizure.2013.11.009","article-title":"Side-effects of antiepileptic drugs: the economic burden","volume":"23","author":"De Kinderen","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2026.05.031_bib0046","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010862","article-title":"The costs of epilepsy in Australia: a productivity-based analysis","volume":"95","author":"Foster","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2026.05.031_bib0047","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0883073819890997","article-title":"Safety and tolerability of adjunctive eslicarbazepine acetate in pediatric patients (Aged 4-17 Years) with focal seizures","volume":"35","author":"Mintz","year":"2020","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2026.05.031_bib0048","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/epi.13993","article-title":"Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double-blind, randomized, parallel-group, multicenter study","volume":"59","author":"Trinka","year":"2018","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126001627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126001627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:54:18Z","timestamp":1784112858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131126001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"alternative-id":["S1059131126001627"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.05.031","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching from oxcarbazepine to eslicarbazepine in patients with focal epilepsy: A systematic review and single-arm meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}